Kyoto Breast Cancer Research Network   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Kyoto Japan (2015)

Organization Overview

First Clinical Trial
2015
NCT02551263
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Kyoto Breast Cancer Research Network

Active Ingredients

Drugs in Phase 3 Trials (1)

palbociclib (ibrance) (1 trial)

Drugs in Phase 2 Trials (5)

durvalumab (imfinzi) (1 trial)

fulvestrant (faslodex) (1 trial)

tipiracil (lonsurf) (1 trial)

tremelimumab (Imjudo) (1 trial)

trifluridine (viroptic) (1 trial)

Drugs in Other Trials (1)

eribulin (halaven) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 7